Thread by @TRUExDEMON

Hey, @Tsiash1 I'm curious how many minutes you actually spent on your research for this stock.

Did you write this out of spite for your assignment or something?

Your research is ankle deep at best, and I resent that you dismissed it as a meme stock.

investorplace.com/2021/11/prog-s…

Do you really have that much hubris that you don't think that retail investors can research this shit too?

If you spent more than thirty minutes moping about having to write something about a stock you didn't know anything about, you'd have realized this company is ready to pop.

You should have noticed that this stock has been shorted by 30% of its free float since it was trading under $1.00 less than a month ago, and that the short reports have continued maintaining.

If you looked at options data, you should have seen the PCR is 0.14 and OI of 250k

Further, this stock went UP after 1.5x-ing its float with two massive dilutions in less than a month, and average shorts are losing by over 100% according to the Ortex Data which you can feel free to ask from any retail investor in $PROG who cares about short interest data.

I'm not annoyed because you trashed the stock In invested in.

I'm annoyed because you spent the first two paragraphs notching about having to write an article about it, then proceeded to shit on it out of spite.

And people actually listen to you. That's the worst part.

This is the most unprofessional financial journalist analysis I've seen this month, and that's saying something after reading @CGasparino's toilet commentary on $AMC.

Grow up and take some pride in your work. Jesus H. Christ...

All you journalists shit on Retail like we are a bunch of rabid dumb-shit gambling addicts armed only with giphs and emojis, when most of us have been betting real money on our painstaking research that you proceed to wipe your ass with because you have supposed "experience"

I challenge you to look again at progenity and take notice that Preclampsia is the 2nd leading cause of maternal death in the developed world, and no other competitor has a rule out test for it anywhere globally.

Every woman should get it just as routinely as an ultrasound

Further, I challenge you to take notice that Progenity had also developed a novel genetic sequencing method which will be applicable in identifying hereditary defects, diseases and propensity for treatable cancers.

No other company I know of has done this.

Finally, I challenge you to take note that Progenity has developed the ONLY oral delivery mechanism for Humira, the world's most profitable drug which nets Abbvie, its developer, $3.9 billion in Q1 of this year alone.

You never even noticed.

All you did was parrot the Motley Fool and their smear piece based on useless fundamentals that failed to even validate their patent releases which have been announced nearly a month ago.

They are an emerging Biotech with a few million in startup capital. Wtf did you expect?

Maybe instead take notice of the fact that Athyrium owns 51% and Vanguard increased their stake by a few million shares in their last 13F released today, along with at least two dozen other wall street funds.

You and I both know earnings dumps are classic accumulation tactics.

You didn't even try with this article.
I'm giving you an F on this assignment.

Go back and do it again.

Bitching*

Sorry my phone hates when I curse.

@threadreaderapp do me a solid and wrap this one up in a bow for me